Episode 289: Paper of The Month - TALAPRO-2 in Nature Medicine

Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature on the use of first-line talazoparib with enzalutamide in patients with HRR-deficient metastatic castration-resistant prostate cancer.
Dr. Fizazi is a medical oncologist at Gustave Roussy, and is a professor of oncology at the University of Paris-Saclay.